Chimeric Antigen Receptor T-Cell Therapy

Patients who receive chimeric antigen receptor (CAR) T-cell therapy or allogeneic stem cell transplants (allo-SCT) often exhibit some form of immunosuppression as a result of their treatment or transplant. In the era of COVID-19, severe disease has emerged as a grave concern in high-risk CAR T-cell therapy and allo-SCT patients who may have weakened immune...

CAR T-cell therapy has gained attention as an increasingly promising cellular therapy. However, while CAR T-cells are highly targeted and effective treatments for certain cancers, they often face mounting obstacles from the tumor microenvironment (TME). Tumors release different immune-suppressing molecules and disrupt the activity of CAR T-cells and other tumor-infiltrating lymphocytes (TILs). Another factor to...